• Mon news: Autolus enters CAR-T race with FDA approval. FDA clears clinical hold on Novavax. AbbVie schizophrenia trial failure. Cigna not pursuing Humana. GSK leaving BIO. See more on our front page

is it true ???

Quote
















  • RTBKPL   Jan 15, 2017 at 10:15: AM
Not sure why Novatis would liquidate the CV Business considering the following:

  • Novartis has inked a worldwide collaboration option deal with Ionis Pharmaceuticals and its subsidiary Akcea Therapeutics for two cardiovascular drugs.
  • Akcea's AKCEA-APO(a)-LRx and AKCEA-APOCIII-LRx are antisense therapeutics with potential to reduce cardiovascular risk in patients with elevated levels of lipoprotein Lp(a), a protein that clogs arteries, or apolipoprotein C3, which research suggests correlates with coronary heart disease. The drugs are in Phase 2 and Phase 1, respectively.
  • The Swiss biopharma pledged a near-term payment of $225 million, including $75 million up front and $150 million in equity investments, for the option. The deal also includes license fees, milestone payments, and royalty payment percentages in the mid-teens to low twenties that could push its total price tag past $1.6 billion.

Do your home work folks....lots of people out to scare folks these days and remember......

Never let the bastards get you down.

RTKBPL
 
























Top Bottom
Back
Quote